Thus, we can highlight that the quantitative determination of BRAF V600 plasma mutations obtained in ctDNA, from metastatic melanoma patients, could serve to monitor treatment, predictor of response and early determination of resistance to treatment with BRAF/ mitogen-activated protein kinase (MEK) inhibitors [64]. The gene discussed is BRAF; the disease is metastatic melanoma.